Curcumin Micelle Composition for Localized Fat Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for reducing localized fat, such as liposuction and non-surgical treatments, are associated with severe side effects, limited administration sites, and lengthy recovery periods, while existing pharmaceutical compositions are often ineffective and pose risks like necrosis and inflammation.

Innovation Solution

A pharmaceutical composition comprising drug-containing micelles with curcumin encapsulated in them, which can be administered locally via subcutaneous injection, providing high stability, high fat tissue bioavailability, and sustained release, promoting apoptosis of local adipocytes to reduce localized fat.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If liposuction is used to reduce localized fat, then fat reduction effectiveness is improved, but side effects and risks increase

Engineering Contradiction:

Improvefat reduction effectivenessVSAvoidside effects and risks

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces the mechanical surgical system of liposuction with a pharmaceutical composition system. The micelle-based drug delivery system uses chemical and biological mechanisms (apoptosis induction, lipolysis) instead of mechanical suction, thereby achieving fat reduction without the severe physical trauma, bleeding, and surgical risks associated with liposuction

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces micelles as an intermediary carrier system between the drug and target tissue. The micelles encapsulate hydrophobic drugs and deliver them specifically to adipose tissue, enabling effective drug delivery while controlling the release profile and minimizing off-target effects, thus reducing side effects while maintaining effectiveness

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If non-surgical localized fat-reducing pharmaceutical compositions are used, then side effects are reduced, but effectiveness decreases

Engineering Contradiction:

Improveside effectsVSAvoideffectiveness

Core Design Contradiction:

Object-affected harmful factorsVSProductivity

Solution Approach 1:

The patent employs a composite micelle system combining hydrophilic and hydrophobic components to create an amphiphilic carrier. This composite structure enables the encapsulation of hydrophobic fat-reducing drugs while maintaining water solubility for injection, and facilitates targeted delivery to adipose tissue through the micelle's surface properties, thereby achieving both safety and effectiveness

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent optimizes multiple parameters of the micelle system including surfactant composition, micelle size, drug loading concentration, and release kinetics. By carefully controlling these parameters, the system achieves sustained release of the drug at the target site, maintaining effective drug concentrations over time while minimizing systemic side effects

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If conventional pharmaceutical compositions are used, then administration is simplified, but stability and bioavailability decrease

Engineering Contradiction:

Improveadministration simplicityVSAvoidstability and bioavailability

Core Design Contradiction:

Ease of operationVSStability of the object's composition

Solution Approach 1:

The micelle acts as an intermediary carrier that solubilizes hydrophobic drugs in aqueous injection media. The surfactant molecules form micellar structures with hydrophobic cores that encapsulate the drug and hydrophilic exteriors that interact with water, enabling stable injection formulations without requiring complex co-solvent systems or special administration procedures

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively reduces localized fat with minimal side effects, offering a safer and more efficient alternative to surgical and non-surgical treatments by promoting apoptosis at the administration site.

Implementation Method 1

drug-containing micelles made of surfactants, and curcumin encapsulated in the micelles

Methodology Applied

Scientific EffectMicelle formation: Surfactant

Implementation Method 2

curcumin encapsulated in said drug-containing micelles

Methodology Applied

Scientific EffectEncapsulation: Absorption (physical)

Implementation Method 3

The present invention can promote apoptosis of the local adipocytes at the administration sites, thereby achieving the goal of reducing localized fat

Methodology Applied

Scientific EffectApoptosis:

Data Source

PatentEP3381451B1Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition

Publication Date: 2025.08.20 CALIWAY BIOPHARM

Figure 1A
Figure 1B
Figure 2A

AI summary

The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.